StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$69.06−5.12 (-6.90%)

Close on Nov 18, 2026Market cap $1.02BP/E –Yield –

Inhibrx Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Inhibrx Biosciences's profit margin for the twelve months ending Dec 31, 2025 was -10773.5%. For fiscal 2025 it was -10773.5%, against 843786.0% the year before. The highest annual figure on record is 843786.0% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-10773.5%−854559.5
FY2024Dec 31, 2024843786.0%+857194.9
FY2023Dec 31, 2023-13408.9%−6783.7
FY2022Dec 31, 2022-6625.3%−5494.5
FY2021Dec 31, 2021-1130.8%−540.1
FY2020Dec 31, 2020-590.7%−201.6
FY2019Dec 31, 2019-389.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-1936.6%+3791.9
Q2 FY2025Jun 30, 2025-2204.2%+41316.0
Q4 FY2024Dec 31, 2024-47865.0%+108975.0
Q2 FY2024Jun 30, 20241858011.0%+2145752.2
Q4 FY2023Dec 31, 2023-5728.5%+9204.0
Q3 FY2023Sep 30, 2023-43520.2%−30813.3
Q2 FY2023Jun 30, 2023-156840.0%−151533.1
Q1 FY2023Mar 31, 2023-287741.2%−284376.9
Q4 FY2022Dec 31, 2022-14932.5%−14190.6
Q3 FY2022Sep 30, 2022-12706.8%−11894.0
Q2 FY2022Jun 30, 2022-5306.9%−3136.0
Q1 FY2022Mar 31, 2022-3364.3%−1194.5
Q4 FY2021Dec 31, 2021-741.9%−106.1
Q3 FY2021Sep 30, 2021-812.8%−465.4
Q2 FY2021Jun 30, 2021-2170.9%−1635.2
Q1 FY2021Mar 31, 2021-2169.7%+134.5
Q4 FY2020Dec 31, 2020-635.8%+5563.8
Q3 FY2020Sep 30, 2020-347.3%+1306.7
Q2 FY2020Jun 30, 2020-535.6%–
Q1 FY2020Mar 31, 2020-2304.2%–
Q4 FY2019Dec 31, 2019-6199.6%–
Q3 FY2019Sep 30, 2019-1654.1%–

More Inhibrx Biosciences figures

See a number that looks wrong?